Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice
- PMID: 27496654
- DOI: 10.1016/j.phrs.2016.05.034
Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice
Abstract
Oxycodone has been used clinically for over 90 years. While it is known that it exhibits low affinity for the multiple opioid receptors, whether its pharmacological activities are due to oxycodone activation of the opioid receptor type or due to its active metabolite (oxymorphone) that exhibits high affinity for the mu-opioid receptors remains unresolved. Ross and Smith (1997) reported the antinociceptive effects of oxycodone (171nmol, i.c.v.) are induced by putative kappa-opioid receptors in SD rat while others have reported oxycodone activities are due to activation of mu- and/or delta-opioid receptors. In this study, using male mu-opioid receptor knock-out (MOR-KO) mice, we examined whether delta-opioid receptor was involved in oxycodone antinociception. Systemic subcutaneous (s.c.) administration of oxycodone (above 40mg/kg) could induce a small but significant antinociceptive effect in MOR-KO mice by the tail flick test. Delta-opioid receptor antagonist (naltrindole, 10mg/kg or 20mg/kg, i.p.) could block this effect. When oxycodone was injected directly into the brain of MOR-KO mice by intracerebroventricular (i.c.v.) route, oxycodone at doses of 50nmol or higher could induce similar level of antinociceptive responses to those observed in wild type mice at the same doses by i.c.v. Delta-opioid receptor antagonists (naltrindole at 10nmol or ICI 154,129 at 20μg) completely blocked the supraspinal antinociceptive effect of oxycodone in MOR-KO mice. Such oxycodone antinociceptive responses were probably not due to its active metabolites oxymorphone because (a) the relative low level of oxymorphone was found in the brain after systemically or centrally oxycodone injection using LC/MS/MS analysis; (b) oxymorphone at a dose that mimics the level detected in the mice brain did not show any significant antinocieption effect; (c) oxycodone exhibits equal potency as oxymorphone albeit being a partial agonist in regulating [Ca(2+)]I transients in a clonal cell line expressing high level of mu-opioid receptor. These data suggest that oxycodone by itself can activate both the mu- and delta-opioid receptors and that delta-opioid receptors may contribute to the central antinociceptive effect of oxycodone in mice.
Keywords: Antinociceptive; DAMGO (PubChem CID: 5462471); Etorphine (PubChem CID: 443407); Morphine (PubChem CID: 528826); Naloxone hydrochloride (PubChem CID: 5464092); Naltrindole hydrochloride (PubChem CID: 24840086); Opioid receptors; Oxycodone; Oxycodone hydrochloride (PubChem CID: 5462350); Oxymorphone; Oxymorphone (PubChem CID: 5284604).
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
-
Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.Brain Res. 2006 Apr 14;1083(1):61-9. doi: 10.1016/j.brainres.2006.01.095. Epub 2006 Mar 10. Brain Res. 2006. PMID: 16530171
-
Characterization of the antinociceptive effects of oxycodone in diabetic mice.Eur J Pharmacol. 2006 Mar 27;535(1-3):145-51. doi: 10.1016/j.ejphar.2006.02.002. Epub 2006 Mar 14. Eur J Pharmacol. 2006. PMID: 16533506
-
Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats.Anesthesiology. 2006 Oct;105(4):801-12. doi: 10.1097/00000542-200610000-00027. Anesthesiology. 2006. PMID: 17006080
-
Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review.Anesth Analg. 2021 Feb 1;132(2):406-419. doi: 10.1213/ANE.0000000000005309. Anesth Analg. 2021. PMID: 33332902 Free PMC article. Review.
-
Ligand-Free Signaling of G-Protein-Coupled Receptors: Relevance to μ Opioid Receptors in Analgesia and Addiction.Molecules. 2022 Sep 8;27(18):5826. doi: 10.3390/molecules27185826. Molecules. 2022. PMID: 36144565 Free PMC article. Review.
Cited by
-
A limited access oral oxycodone paradigm produces physical dependence and mesocorticolimbic region-dependent increases in DeltaFosB expression without preference.Neuropharmacology. 2022 Mar 1;205:108925. doi: 10.1016/j.neuropharm.2021.108925. Epub 2021 Dec 15. Neuropharmacology. 2022. PMID: 34921830 Free PMC article.
-
Recommended Opioid Receptor Tool Compounds: Comparative In Vitro for Receptor Selectivity Profiles and In Vivo for Pharmacological Antinociceptive Profiles.ACS Pharmacol Transl Sci. 2024 Dec 31;8(1):225-244. doi: 10.1021/acsptsci.4c00604. eCollection 2025 Jan 10. ACS Pharmacol Transl Sci. 2024. PMID: 39816790
-
Intravenous Oxycodone Versus Other Intravenous Strong Opioids for Acute Postoperative Pain Control: A Systematic Review of Randomized Controlled Trials.Pain Ther. 2019 Jun;8(1):19-39. doi: 10.1007/s40122-019-0122-4. Epub 2019 Apr 19. Pain Ther. 2019. PMID: 31004317 Free PMC article. Review.
-
The Agonist of Adenosine A1 Receptor Induced Desensitization of delta Opioid receptor-mediated Raf-1/MEK/ERK Signaling by Feedback Phosphorylation of Raf-1-Ser289/296/301.Neurochem Res. 2023 May;48(5):1531-1542. doi: 10.1007/s11064-022-03843-2. Epub 2022 Dec 16. Neurochem Res. 2023. PMID: 36525124
-
Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments.Pharmacol Rev. 2023 Nov;75(6):1062-1118. doi: 10.1124/pharmrev.121.000506. Epub 2023 Jun 15. Pharmacol Rev. 2023. PMID: 37321860 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous